Получение, определение и свойства фактора XII плазмы крови человека
Диссертация
В соответствии с этим поставлены основные задачи: разработать метод выделения высокоочищенных препаратов фактора ХП и его активного фрагмента Р-ХИаисследовать свойства полученных препаратовизучить возможность автоактивации фактора XII под действием его активного фрагмента (3-ХПаразработать метод определения фактора XII и его активной формы ХПаизучить действие лекарственных препаратов… Читать ещё >
Содержание
- Список сокращений
- Глава 1. ОБЗОР ЛИТЕРАТУРЫ
- 1. 1. Участие фактора XII в регуляции активности протеолити-ческих систем плазмы крови
- 1. 2. Контактная система активации протеолиза
- 1. 2. 1. Структурно-функциональные свойства факторов контактной системы
- 1. 2. 1. 1. Фактор ХП свертывания крови
- 1. 2. 1. 2. Высомолекулярный кининоген
- 1. 2. 1. 3. Прекалликреин и калликреин плазмы крови
- 1. 2. 1. 4. Фактор XI свертывания крови
- 1. 2. 2. Механизм активации контактной системы на полианионной поверхности
- 1. 2. 3. Новая концепция активации контактной системы на поверхности эндотелиальных клеток
- 1. 2. 1. Структурно-функциональные свойства факторов контактной системы
- 1. 3. Методы выделения и определения фактора ХП
- ЭКСПЕРИМЕНТАЛЬНАЯ ЧАСТ
- Глава I. МАТЕРИАЛЫ И МЕТОДЫ ИССЛЕДОВАНИЯ
- 2. 1. Материалы
- 2. 2. Методы
- 2. 2. 1. Химические и кинетические методы
- 2. 2. 2. Физико-химические методы
- 2. 2. 3. Математические методы анализа полученных результатов
- 3. 1. Получение, очистка и характеристика очищенных препаратов фактора XII и его фрагмента — ß--ХПа из сыворотки крови человека
- 3. 1. 1. Метод очистки фактора XII, ?- ХПа и прекалликреина
- 3. 1. 2. Физико-химические и энзиматические свойства фактора ХП,
- 3. 2. Изучение механизмов активации фактора ХП
- 3. 2. 1. Автоактивация фактора ХП
- 3. 2. 2. Действие активаторов плазминогена, входящих в состав лекарственных средств на фактор ХП и прекалликреин
- 3. 3. Разработка метода одновременного определения фактора ХП, прекалликреина и их активных форм в плазме крови человека с использованием хромогенных субстратов
- 3. 4. Активность и роль фактора ХП и других компонентов контактной системы активации протеолиза при патологии
- 3. 4. 1. Действие эластазы из полиморфноядерных лейкоцитов на фактор ХП и другие компоненты контактной системы активации протеолиза
- 3. 4. 2. Определение фактора ХП, прекалликреина, и их активных форм при перитонитах
- 3. 4. 3. Определение фактора ХП, прекалликреина, и их активных форм при миелобластном лейкозе
Список литературы
- Андреенко Г. В.
- Фибринолиз: Биохимия, физиология, патология. //М., МГУ, 1979, 351. Баркаган З. С., Момот А.П.
- Основы диагностики нарушений гемостаза. // Издательство «Ньюдиамед-АО», Москва, 1999, 64−129.
- Доценко ВЛ., Нешкова Е. А., Яровая Г. А.
- Воспаление: Новые аспекты старой проблемы. // Учеб. Пособие. Российская медицинская академия последипломного образования. Москва, 1998, 31−33.
- Доценко ВЛ., Спирина А.Я., Макинский А.И., Нешкова Е.А., Ёршикова Ю. Е., Яровая Г. А.
- Эластаза лейкоцитов в плазме крови больных туберкулезом и её роль в нарушении регуляции процессов свертывания крови. // Вопр. мед. химии, 2000,46 № 2: 176−183.
- Ангиотеизии-превращающий фермент его физиологическая роль. // Вопросы
- Медицинской химии, 2001,47 вып.1: 43−54. Еремин Г. Ф., Архипов А.П.
- Система регуляции агрегатного состояния крови в норме и патологии. //М., 1982-С: 129 132.
- Крижевская Ю.В., Яровая Г. А., Доценко В.Л.
- Получение и некоторые свойства фактора Хагемана и его активного фрагмента из сыворотки крови человека.//Биохимия, 1981,46: 1510−1517.
- Крижевская Ю. В., Доценко В. Л.,. Яровая Г. А.
- Хроматографический метод определения содержания фактора Хагемана (ХП фактора свертывания) в сыворотке крови человека. // Вопросы мед. химии, Москва, 1982 (2). 128−132.1. МАУРЕР Г.
- ДИСК-ЭЛЕКТРОФОРЕЗ. Теория и практика электрофореза в полиакриламидном геле. Издательство «МИР» Москва 1971.
- Нартикова В.Ф., Пасхина Т.С.
- Унифицированный метод определения активности а-1-антитрипсина и а-2-макроглобулина в сыворотке крови человека. //Вопросы мед. химии. 1977,25, вып. 4: 492−497.
- Пасхина Т.С., Доценко В. Л., Блинникова Е.И.
- Калликреиноген сыворотки крови человека. Метод определения и некоторые свойства. // Биохимия, 1973, 38, № 2: 420−423.1. Фибринолиз.
- Современные фундаментальные и клинические концепции. Ред. Гаффни П. Д., Балкув
- Улютина С., М., // Медицина, 1982. Хашен Р. и Шейх Д.
- Очерки по патологической биохимии". //Изд. «Медицина», Москва, 1981, 126−147. Яровая Г. А.
- Калликреин-кининовая система: новые факты и концепции (обзор). // Вопр. мед. химии, 2001, 47: 20−42.
- Adam A., Albert A., Calay G., Closset J., Damas J., Franchimont P.
- Human Kininogens of Low and High Molecular Mass: Quantification by Radioimmunoassay and Determination of Reference Values. // Clin. Chem., 1985- 31: 423−426.
- Asano M., Inamura N., Hatori C., Sawai H., Fujiwara Т., Abe Y., Kayakiri H., Satoh S., Oku Т., Nakahara K.
- Discovery of active nonpeptide bradykinin B2 receptor antagonists. // Immunopharmacology, 1999, 43(2−3): 163−168.1. Bachmann F.
- Fibrinolysis. // In: Thrombosis and Haemostasis.-Eds. Verstraete M., Vermylen J., Lijnen H. R., Arnout J., Leuven, 1987,227—265.
- Bagdasarian A., Talamo R.C., Colman R.W.1.olation of high- molecular weight activators of prekallikrein. // J. Biol. Chem., 1973, 248. 3456−3463.
- Barnathan E. S., Kuo A., Van der Keyl H., McCrae K. R., Larsen G. R., Cines D. B. Tissue-type plasminogen activator binding to human endothelial cells. Evidence for two distinct binding sites. // J. Biol. Chem., 1988,263: 7792—7799.
- Barret A.J., Rawlings N.D., Davies M.E., Machleidt W., Salvesen G., Turk V. Proteinases inhibitors. // J. Biol. Chem., 1986,260: 8610 8617.
- Bhoola K.D., Figueroa CD., Worthy K.
- Bioregulation kinms: kallikreins, kinmogens and kinmases. // Pharmacol. Rev., 1992, 44:1 -60.
- Boeckmann S., Schuh K, Wartner U., Gera L.
- A new type of bradykinin B2 receptor antagonists: bradykinin analogs with N-alkyI amino acids at position 2. // Immunopharmacology., 1996, 33: 73−80.1. Bradford M.
- A rapid and sensitive method of the quantitation ofmicrogram quantities of protein utilizing the principle of protein-dye bilding. // Anal.Biochem., 1976,72: 248−254.
- Bradford H.N., Jameson B.A., Adam AA., Wassell R.P., Colman R.W. Contiguous binding and inhibitory sites on kininogens required for the inhibition of platelet calpain. //J. Biol. Chem., 1993,268: 26 546 26 551.
- Brunee T., La Porta C., Reddigari S.R., Salemo V.M., Kaplan A.P., Silverberg.-M. Activation of factor XI in plasma is dependent on factor XII. // Blood 1993, 81: 580−586.
- Carvalho A.C., DeMarinis S., Scott C.F., Silver L.D., Schmaier A.H., Colman R.W. Activation of the contact system of plasma proteolysis in the adult respiratory distress syndrome. //J.Lab.Clin.Med., 1988, 112: 270−7.1. Cochrane C.G., Wuepper K.
- The first coirponent of the kinin forming system in human and rabbit plasma. Its relationship to clotting factor XH /Hageman factor/. J.Fxo.Med., 1971,134: 986−1004.
- Cochrane C.G., Revak S.D., Wuepper K.D.
- Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein. // J. Exp. Med., 1973, 138: 1564−1583.1. Cochrane C.G., Revak S.D.
- Dissemination of contact activation in plasma by plasma kallikrein. // J. Exp. Med., 1980,152: 608−619.
- Collen D., Zamarron C., LijnenJL R., Hoylaerts M.
- Activation of plasminogen by pro-urokinase. // J. Biol. Chem., 1986, 261: 1259—1266. Collen D.
- The plasminogen (Fibrinolytic) system // Thromb. Haemostas., 1999, 82 (2): 259−270. Colman R.W.
- Activation of plasminogen by human plasma kallikrein // Biochem. Biophys. Res. Commun., 1969, 35: 273−278.1. Colman R.W., WongS.
- Handbook of Experimental Pharmacology 25(Erdos, E.G., ed) Springer-Verlag, Berlin, 1979, 569−607.1. Colman R.W.
- Surface-mediated defence reactions. The plasma contact activation system. // J. Clin Invest, 1984, 73: 1249 1253.1. Colman R.W.1.teractions between the contact system, neutrophils and fibrinogen. // Adv. Exp. Med. Biol., 1990,281: 105 120.1. Colman R.W.
- Factor XII activation and inhibition in inflammation. // Agent. Action. Suppl., 1993, 42: 125 143.1. Colman R.W.1.hibitory and antiadhesive properties of human kininogens. // Immunopharmacology., 1996, 32: 9 18.
- Colman R.W., Pixley R,"Najamunnisa S. et al.
- High molecular weight kininogen binds to the vitronectin binding domain (s) on the urokinase receptor on human endothelial cells. / /Circulation., 1996, 94:1−42.
- Colman R. W., Schmaier A.H.
- Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive and proinflammatory attributes. //Blood, 1997,90: 3819−3843.
- Colman R.W., Pixley R.A., Najamunnisa S., Yan W.-Y., Wang J., Mazar A., McCrae K.R.
- Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. // J. Clin, invest., 1997, 100: 14 811 487.
- Colman R. W, Lin Y., Johnson D., Mousa S.A.1.hibition of angiogenesis bv peptides derived from kimnogen. // Blood., 1998, 92(Suppl 1): 174a.
- D’Orleans-Juste P., de Nucci G., Vane J.P.
- Kinins act on B1 and B2 receptors to release conjointly endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells. // Br.J. Pharmacol., 1989, 96: 920−926.
- Dano K., Andreasen P. A., Grondahl-Hansen J., Kristensen P., Nielsen L. S., Skriver L Plasminogen activators, tissue degradation, and cancer. // Adv. Cancer Res., 1985, 44: 139— 266.
- Dedio J., Jahnen-Dechent W., Bachmann M., Muller-Esterl W.
- The multiligand-binding protein gClqR, putative Clq receptor, is a mitochondrial protein. //J. Immunol., 1998, 160: 3534−3542.
- Dedio J., Mueller-Esterl W.
- Kininogen binding protein p33/gClqR is localized in the vesicular fraction of endothelial cells. //FEBS Lett., 1996, 399: 255−2558.
- DeLa Cadena R.A., Wachtvogel Y.T., Colman R.W.
- Contact activation pathway: Inflammation and coagulation. // Hemostasis and Trombosis, 1974, 219 240.1. DeLa Cadena R., Colman R.
- The sequence HGLGHGHE-QQHGLGHGH in the light chain of high molecular weight kininogen serves as a primary structural feature for zinc-dependent binding to an anionic surface. //Protein Sci., 1992,1:151−160.
- Dotsenko V.L., Nenasheva N.M., Neshkova E. A., Yarovaya G. A.
- Mechanism of activation of the kallikrein-kinin system in plasma of patients with atopic allergic diseases. // Advances in Experimental Medicine and Biology, Kinin V Ed. Abe K., Moriya H., Fumii S., New York: Plenum Press 1989, B: 515−521.
- Dotsenko V. L, Neshkova E. A., Yrovaya G. A.
- The regulating interrelationship of some serine proteinases from leukocyte with the r human plasma kaUirrein-kinin system. // Agents and Actions, Suppl., 1992, 38: 144−156.
- Dunn J.T., Silverberg M., Kaplan A.P.
- The cleavage and formation of activated human Hageman factor by autodigestion and by kallikrein. //J. Biol. Chem., 1982,257: 1779−1784.1. Earl W., Davie E.W.
- The blood coagulation Factors: Their cDNAs, Genes, and Expression // Heamostasis and Thrombosis, 2 nd.ed. (eds. Colman et al.) 1987, 242 265.1. Ellis E.F.
- New Trends in Lipid Mediators Research, Basel, Karger, // 1990: 129 1451. Farmer S.G. Burch R.M.
- Pharmacology of bradykinin receptors in bradykinin antagonists basic and clinical research. // 1991, Burch RM ed Marcel Dekker Inc, N Y: 1 -32.1. Fritz H.
- Proteinase inhibitors in severe inflammaatory processes (septic shock and experimental endotoxaemia): biochemical, pathohysiological and therapeutic aspects. // 1980, In: «Protein degradation in health and disease». Ciba Faundation Symp. 75: 351−379
- Fritz H., Jochum M., Duswald K.H., Dittmer H., Kortmann H.
- Granulocyte proteinases as mediators of unspecific proteolysis in inflammation. //, 19 841.: «Selected topics in clinical enzymology». Washington, 2: 305−328.
- Fujikawa K., Heimark R.L., Kurachi K., Davie E.W.
- Activation of bovine factor XII (Hageman factor) by plasma kallikrein. // Biochemistry, 1980, 19: 1322−1330.1. Fujikawa K., Davie E.W.
- Human Factor XH (Hageman factor). // Methods Enzymol., 1981, 80: 198 211. Fujikawa K., McMullen B.A.
- Amino acid sequence of human p-factorXna. // Biol. Chem, 1983, 258: 10 924−10 933.
- Fujikawa K., Chung D.W., Hendrickson L., Dane E.W.Amino acid sequence of human factor XI, a blood coagulation factor with four tandem repeats that are highly homologous with plasma prekallikrein. // Biochemistry, 1986,25: 2417−2421.
- Factor XI activation in a revised model of blood coagulation I I Science, 1991,253: 909 912.
- Ghebrehiwet B., Silverberg M., Kaplan A.P.
- Activation of the classical pathway of complement by Hageman factor fragment. // J. Exp. Med., 1981,153: 665−676.
- Goldsmith G.H., Saito H" Ratnoff O.D.
- The activation of plasminogen by Hageman factor (factor XII) and Hageman factor fragments // J. clin. Invest., 1978,62: 54−60.
- Griep M.A., Fujikawa K., Nelsestuen G.L.
- Binding and activation properties of human factor XII, prekallikrein and derived peptides with acidic lipid vesicles. //Biochemistry, 1985,24: 4124−4130.
- Griffin J.H., Cochrane C.G.
- Human factor XII /Hageman factor/. // Methods in Enzymology, Ed. Lorand L., Academic Press, 1976,45B: 56−63.
- Gurewich V., Johnson, M., Loza J.P., Pannell R.
- Pro-urokinase and prekallikrein are both associated with platelets Implications for the intrinsic pathway of fibrinolysis and for therapeutic thrombolysis // FEBS Lett., 1993, 318: 317−321.
- Gustafson E.J., Schutsky D., Knight L.C., Schmaier A.H.
- High molecular weight kininogen binds to instimulated platelets. // J. Clin. Invest., 1986, 78: 310−318.
- Gustafson E., Lukasiewicz H., Wachtvogel Y., Norton K., Schmaier A., Niewarowski S., Colman R.
- High molecular weight kininogen inhibits fibrinogen binding to cytoadhrsis and platelets. // J. Cell Biol., 1989,109: 377 387.
- Herwald H., Hasan A. A. K, Godovac
- Zimmermann J., Schmaier A.H., Muller Esterl W.- Identification of an endothelial cell binding site on kininogen domain D3. // J. Biol. Chem., 1995, 270: 14 634 -14 642.
- Herwald H., Dedio J., Kellner R., Loos M., Muller Esterl W. Isolation and characterization of the kininogen-binding protein p33 from endothelial cells. Identity with the gClq receptor. // J. Biol. Chem., 1996, 271: 13 040 — 13 047.
- Higashiyama S., Ohkubo I., Ishiguro H., Sasaki M.
- Human high molecular weight kininogen as a thiol proteinase inhibitor: Presence of the entire Inhibition capacity in the native form of heavy chain. // Biochemistry, 1986,25: 1669−1671.
- Hoem N-O., Johansen H.T., Johannesen S., Briseid K.
- Rocket immunoassay of high and low molecular weight kininogens in human plasma. // Adv. Exp. Med. Biol., 1989,247A: 337 343.
- Holmes W. E., Nelles L., Lijnen H. R, Collen D.
- Primary structure of human a2-antiplasmin, a serin protease inhibitor (serpin). // J. Biol Chem., 1987,262: 1659−1664.
- Horlick R.A., Ohlmeyer M.H., Stroke I.L.
- Small molecule antagonists of the bradykinin Bi receptor. // Immunopharmacology, 1999. 43(2−3): 169−177.1.hinose A., Fujikawa K., Suyama T.
- The activation of pro- urokinase by plasma kallikrein and its inactivation by thrombin. // J, Biol. Chem., 1986, 261: 3486—3489.
- Jochum M., Machleidt W., and Fritz H.
- Phagocyte proteinases in multiple trauma and sepsis: pathomechanims and related therapeutic approaches. // Handbook of Mediators in Septic Shock, CRC Press. London, Tokyo, 1993, 335−361.
- A prealbumin activator of prekallikrein. II. Derivation of activators of prekalli-krein from active Hageman factor by digestion with plasipin. // J.Fxp. Med., 1971, 133: 696−712.1. Kaplan A., Austen K.F.
- Activation and control mechanisms of Hageman factor-dependent pathways of coagulation, fibrinolysis and kinin generation and their contribution to the inflammatory response. // J. Miergy Clin. Iiwnunol., 1975, 56: 491−506.
- Kaplan A.P., Meyer M.L., Mandle R.J.
- Kaplan A.P., Silverberg M.
- The coagulation-kinin pathway of human plasma. // Blood, 1987, 70: 1−15.
- Kellermeyer W.F., Kellermeyer R.W.
- Hageman factor activation and kinin formation in human plasma induced by cellulose sulfate solutions. //Proc.Soc. Exptl.Biol. Med., 1969,130: 1310−1314.
- Khan M.M., Yamamoto T- Araki H- Shibuya Y- Kambara R.
- Role of Hageman factor/kallikrein-kinin system in pseudomonal elastase-induced shockmodel.// BiochimBiophysActa, 1993, 1157:119−26
- Kitamura N., Kitagawa H., Fukushima D., Takagaki Y., Miyata T., Nakanishi S. Structural organization of the human kininogen and a model for its evolution. // J Biol Chem 1985,260: 8610 8617.
- Koide T., Foster D., Yoshitake S., Davie E. W.
- Amino acid sequence of human histidine-rich glycoprotein derived from the nucleotide sequence ofitsDNA. // Biochemistiy, 1986, 25: 2220—2225.
- Kunapuli S.P., DeLa Cadena R. A., Colman R.W.
- Deletion mutagene-sis of high molecular weight kininogen light chain: Identification of two anionic surface binding subdomains.// J. Biol. Chem., 1993,268: 2486 2492.1. Kurachi K., Davie E.W.
- Activation of human factor XI (plasma tromboplastin antecedent) by factor Xlla, (activated Hageian factor). // Biochemistry, 1977, 16: 5831.1. Kwaan H. C., Keer H. N.
- Fibrinolysis and cancer. // Semin. Thromb. Hemost., 1990, 16: 230—235. Laemmli U.K.
- Cleavage of structural proteins during the assembly of the head ofbacteriophage T4. // Nature, 1970, 227: 680−685.1.ngdell R.D., Wagner R.H., Brinkhous K.M.
- Effect of antihemophilic factor on one-stage clotting tests: a presumptive test for hemophilia and a single one-stage- anti-hemophilic factor assay procedure. // J. Lab. Clin. Med., 1953,41: 7637−7647.1.nich C., Pannell R., Gurewich V.
- Assembly and activation of the intrinsic fibrinolytic pathway on the surface of human endothelial cells in culture // Thromb. Haemostasis, 1995, 74: 698 703.1.jnen H. R., Zamarron C., Blaber M., Winkler M. E., Collen D.
- Activation of plasminogen by pro-urokinase. // J. Biol. Chem., 1986,261: 1253—1258.1.za J.P., Gurewich V., Johnstone M., Pannell R
- Platelet-bound prekallikrein promotes pro-urokinase-induced clot lysis a mechanism for targeting the factor XII dependent intrinsic pathway of fibrinolysis //Thromb. Haemostasis, 1994, 71: 347−352.
- Miiller Esterl W., Fritz H., Machleidt W., Ritonja A., Brzin, J., Kotnik M., Turk V. Kellermann J., Lottspeich F.
- Human plasma kininogen are identical with a-cysteine proteinase inhibitors. // FEBS Lett 1985, 182: 310−314.
- Muller Esterl W., Iwanaga S., Nakanishi S. Kinlnogens revisited. // TIBS 1986- 11: 336.1. MacFarlane R.G.
- An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. //Nature, 1964,202: 498−499.1. Mandle R.J., Kaplan A.P.
- Human plasma prekallikrem: Mechanism of activation by Hageman factor and participation in Hageman-factor-dependent fibrinolysis //J. Biol. Chem., 1977,252: 6097−6104.
- Mandle R. Jr, Colman R.W., Kaplan. A.P.1.entification of prekallikrein and high molecular weight kininogen complex in plasma. // Proc. Natl. Acad. Sci. USA., 1976, F3: 4179−4183.1. Marceau F.
- KininBl receptors: a review. // Immunopharmacology, 1995,43: 1 -26. McMullen B.A., Fujikawa K. J.
- Amino acid sequence of heavy chain of human a- factor Xlla. // Biol. Chem., 1985, 260 5328−5341.
- Miles L. A, Greengard J.S., Griffin J.H.
- A comparison of the abilities of plasma kallikrein, a- factor Xlla, factor XIa and urokinase to activate plasminogen // Thromb. Res.,, 9: 407−417.
- Mitropoulos K.A., Esnouf M.P.
- High affinity binding of factor Xlla to an electronegative surface controls the rates of factor XII and prekallikrein activation in vitro. // Thromb. Res., 1999,94: 117−129.1. Mitropoulos K.A.
- The levels of factor Xlla generated in human plasma on an electronegative surface are insensitive to wide variation in the concentration of FXH, prekallikrein, high molecular weight kininogen or FXI. // Thromb. Haemost., 1999, 82: 1033−1040.
- Movat H.Z., Ozge-Anwar A.H.
- The contact phase of blood coagulation: clotting factors XI and XII. their isolation and interaction. // J. Lab. Clin. Med., 1974, 84: 861−878.1. Movat H.Z.
- The plasma kallikrein-kinin system and its interrelationship with other components of blood. // Handbook of Experimental pharmacology. Ed. Erdos E.G.-Heidelberg-New York: Springer Verlag, 1979,255: 2−89.1. Mueller R. L., Scheidt S.
- Histoty of drugs for thrombotic disease. // Discovery, development, and directions for the future. Circulation, 1994, 89: 432—449. Murray S.R., ChaoJ., Chao L.
- Evalution of the kallikrein gene family // Agent. Action. Supl., 1992,38(1): 26 33. Nakajima K., Powers J.C., Ashe B.M., Zimmerman M.
- Mapping the extended substrate bilding site of cathepsin G and human leukocyte elastase. Studies with peptide substrate related to the ai-proteinase inhibitor reactive site. // J. Biol. Chem., 1979, 254: 4027−4032
- Nuigens J.H., Huijbregts C.C., Eerenberg Belmer A.J.M., Meijers, J.C.M., Bouma B.N. Hack E.
- A familial hemorrhagic trait associated with a deficiency of a clot-pro'moting fraction of plasma. //J. Clin. Jnvest., 1955,34: 602−613.
- Ratnoff O.D., Davie E.W., Mallctt D.L.
- Studies on the action of Hageman factor evidence that activated Hageman factor in turn activates plasma thromboplastin antecedent. // J. Clin. Invest. 1961,40: 803−819.1. Ratnoff O.D., Davie E.W.
- The biology and pathology of the initial coagulation reactions. // J. Clin. Unvest., 1961,41: 803−824.1. Ratnoff O.D., Davie E.W.
- Partial purification kallikreinogen, its activation by Hageman factor. // Biochemistry, 1962, 1: 967−978.
- Rapaport S.I., Schiffinan S., Patch M.J., Ames S.B.
- The importance of activation of antihemophilic globulin and proaccelerin by traces of thrombin in the generation of intrinsic prothrombinase activity. // Blood, 1963, 21: 221.
- Reissmann S., Greiner G., Seyfarth L., Paegelow I., Werner H.- Vietinghoff G., Boeckmann S., Schulz E., Wartner U., Gera L.
- A new type of bradykinin B2 receptor antagonits: bradykinin analog with N-alkyl amino acids at position 2 // 1996, Immunopharmacology, 33: 73−80.
- Retzios A.D., Rosenfeld R, Schifiman S.
- Effects of chemical modifications on the surface- and protein-binding properties of the light chain of human high molecular weight kininogen // J. Biol. Chem., 1987,262: 3074 -3081.
- Revak S.D., Cochrane C.G., Johnston A.R., Johnston A.R.
- Structural changes accompanying enzymatic activation of human Hageman factor. // J.Clin. Invest, 1974, 54: 619−627.1. Revac S.D., Cochrane C.G.
- Hageman factor: its structure and modes of activation. // Thromb. Haemost., 1976, 35, № 3: 570−575.1. Robert W.1.hibitory and antiadhesive properties of human kininogens. // Immunopharmacology, 1996. 32: 9−18.1. Rodell T.C.
- The kallikrein/lanin system and kinin antagonists in trauma // Immunopharmacology, 1996. 33:279−283
- Rojkjaer R., Motta G., Hasan A.AK., Schousboe I., Schmaier A.H.
- Factor XII does not initiate prekallikrein activation on endothelial cells. // Thromb.
- Heamostasis, 1998, 80: 74−81.1. Rojkjar R., Schmaer A.H.
- Activation of the plasma kallikrein/kinin system on endothelial cell membranes. // Immunopharmacology. 1999 43,109−114.1. Rojkaer R., Schmaier A.H.
- Activation of the plasma kallikrein/kinin system on endothelial cells. // Proc. Assoc. Am. Phys., 1999, 111: 220−227.
- Rosenthal R.L., Dreskin O.H., Rosenthal N.
- New haemophilia-like disease caused by deficiency of a third plasma thromboplaslin factor. // Proc. Soc. Exp. Biol. Med. 1953, 82: 171−174.
- Sakurai H., Maeda M., Murase M., Koyama T., Hayakawa M.
- Hemofiltration removes bradykinin generated in the priming blood in cardiopulmonary bypass during circulation. // Ann.Thorac.Cardiovasc.Surg., 1998,4: 59−63.
- Schiffman S., Rapaport S T., Uare A G.
- Partial purification and characterization of contact activation cofactor. // Proc. Soc. Exp. Biol. Med., 1960, 105: 453−465.
- Schiffman S., Rapaport S T., Uare A G.
- Partial purification and characterization of contact activation cofactor. // Proc. Soc. Exp. Biol. Med., 1960,105: 453−465.1. Schmaier A. H.
- Contact activation: A revision. // Thromb. Haemostas., 1997, 78: 101—107. Schmaier A.H., Kuo A., Lundberg D., Myrray S., Cines D.B.
- The expression of high molecular weight kmmogen on human umbilical vein endothehal cells // J. Biol. Chem., 1988,263: 16 327−16 333.
- Schmaier A.H., Rojkjaer R.
- Activation of the Plasma Kallikrein/Kinin System on Cells: A Revised Hypothesis. // Thromb. Haemostasis, 1999, 82:226−233.
- Schmitt M., Harbeck N., Thomssen C., Wilhelm 0., Magdolen V., Reuniig U., Hofier H., Janicke F., GraefFH.
- Clinical impact of the plasminogen activation system in tumor invasion and metastasis: Prognostic relevance and target for terapy. // Thromb. Haemostas., 1997, 78: 285−296.
- Schousboe L, Feddersea K., ROjkjcer F.
- Factor Xlla is a Kinetically Favorable Plasminogen Activator., // Thromb. Hemos., 1999- 82: 1041−1046.1. Scott C.F., Colman R.W.
- Function and immunochemistry of prekallikrein-high weight kininogen complex in plasma. // J. Clin. Invest., 1980, 65: 413 421.
- Scott C.F., Silver L.D., Schapira M., Colman R.W.
- Cleavage of human high molecular weight kininogen markedly enhances its coagulant activity. // J. Clin. Invest., 1984, 73: 954 962.
- Scott C.F., Silver L.D., Purdon A.D., Colman R.W.
- Cleavage of human high molecular weight kininogen by factor XIa in vitro. II J. Biol. Chem., 1985,260: 10 856 10 863.
- Silverberg M., Dunn J.T., Garen L., Kaplan, A.P.
- Autoactivation of human Hageman factor. Demonstration utilizing a synthetic substrate. //J. Biol. Chem., 1980,255: 7281−7286.
- Silverberg M., Kaplan A.P.
- Enzymatic activities of human Hageman factor. //Metods in enzymology, 1988, 163M: 68−78. Smith D., Gilbert M., Owen W. G.
- Tissue plasminogen activator release in vivo in responce to vasoactive agents. // Blood, 1983. 66: 835— 839.
- Sottrup-Jensen L., Stepanic T.M., Kristensen T., Wierzbicki D.M., Jones C. M., Lonblad P B., Magnusson S., Petersen T.E.
- Primary structure of human a2-macroglobulin. V, The complete structure. // J. Biol. Chem. 1984,259:8318—8327.
- Speer R.J., Ridqway H., Hill J.M.
- Activated human Hageman Factor. IXIV. // Thromb. Diath. Haemor., 1965, 14: 1−14.
- Stadnicki A., DeLa Caderia R., Sartor R.B., Kettner C.A., Colman R.W.
- The contact system in experimental enterocolitis. // Immunopharmacology., 1996, 33:314.316.
- Stewart J.M., Gera L, York E.J., Chan D C., Bunn P.
- Bradykinin antagonist: present progress and future prospects // Immunopharmacology, 1999, 43(2−3): 155−161.1. Stewart J.M.
- Mediators of the Inflammatory Processes, Amsterdam, 1989, 189−217. Takagaki Y., Kitamura N., Nakanishi S.
- Rocket immunoassay of high and low molecular weight kininogens in human plasma. // J. Biol. Chem., 1985,260, 8601 8609.
- Tankersley D.L., Finlayson J.S.
- Kinetics of activation and autoactivation of human factor XII. // Biochemistry, 1984,23: 273−279.
- Tans G., Rosing J., Griffin J.H.
- Sulfatide-dependent autoactivation of human blood coagulation factor XII (Hageman factor). //J. Biol. Chem., 1983,258: 8215−8222.
- Tans G, Janssen-Claessen T, Rosing J, Griffin JH.
- Studies on the effect of serine protease inhibitors on activated contact factors. Applications in amidolytic assays for factor Xlla, plasma kallikrein and factor XIa. // Eur. J. Biochem., 1987, 164: 637−642.
- Tayeh M.A., Olson S.T., Shore J.D.
- Surface-induced alterations in the kinetic pathway for cleavage of human high molecular weight kininogen by plasma kallikrein. // J. Biol. Chem., 1994,260: 16 318 16 325.
- The Kallikrein Kinin System in Health and Disease. Munich: Limbach Verlag Braunschweig, 1989, 374.'
- Thsby S., Kumar A., Joseph M.
- Expression of active human factor DC in transfected cells. // Nature, 1985, 316: 271. Trautshold L., Werle E.
- Spektrophotometrische bestimmung des kallikreins und seiner inaktivatoren. // Hoppe-Seyler's Z.Physiol.Chem., 1961, 325: 52−81.
- The binding of high molecular weight kinmogen to cultured human en-dothehal cells. //
- Blood, 1988, 71: 1268 1276.1. Visser L., Blout E.R.
- The use ofp-nitrophenyl-N-tetrabutoxycarbonyl-L-alaninate forelastase. // Biochem. Biophys. Acta., 1972, 268: 257−260.
- Wachtfogel Y.T., DeLa Cadena R. A., Colman RW.
- Structural biology, cellular interactions and pathophysiology of the contact system. // Throm. Res., 1993, 72: 1−21.
- Wachtvogel Y.T., DeLa Cadena R.A., Kunapuli S.P., Rick L., Miller M., Schultze R.L., Altieri D C., Edgington T.S., Colman RW.
- High molecular weight kinmogen bind to Mac-1 on neutrophils by its heavy chain (domain 3) and its chain (domain 5). // J. Biol. Chem., 1994, 269: 19 307 19 312.
- Weiss A., Galiin J., Kaplan A.
- Fletscher factor deficiency. Diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis. chemotactic*activity and kinin generation. // J. Clin. Invest, 53: 622−633.
- Williams K.W., Soderberg L.
- A carrier ampholyte for isoelectric focusing. // International Laboratory, Jan/Feb., 1979. Yarovaya G.A., Dotsenko V.L., Neshkova H.A.
- The regulating interrelationship of some serine proteinases from leukocyte with the human plasma kallikrein-kinin system. // Agent Action (Suppl), 1991, 38: 144 156.
- Zini J.M., Schmaier A.H., Cines D.B.
- Bradykimn regulates the expression of kininogen binding sites on endothelial cells // Blood, 1993, 81: 2936−2946.